Mersana Therapeutics, Inc. Contracts & Agreements

Exchange Agreement, dated as of December 19, 2024, by and among Mersana Therapeutics, Inc. and the holders of the common stock listed on Schedule I attached thereto (Filed With SEC on December 19, 2024)

Form of Pre-Funded Warrants (Filed With SEC on December 19, 2024)

Sales Agreement, dated February 28, 2024, by and between the Company and Cowen and Company, LLC (Filed With SEC on February 28, 2024)

Non-Employee Director Compensation Policy (Filed With SEC on February 28, 2024)

Offer Letter, dated (Filed With SEC on February 28, 2024)

Amendment No. 1 to the Research Collaboration and License Agreement (effective February 2, 2022), dated July 14, 2023, by and between Mersana Therapeutics, Inc. and Janssen... (Filed With SEC on November 7, 2023)

Amendment No (Filed With SEC on November 7, 2023)

Retirement and Separation Agreement, dated S (Filed With SEC on November 7, 2023)

Offer Letter, dated September 5, 2023, by and between Mersana Therapeutics, Inc. and Martin Huber (Filed With SEC on November 7, 2023)

Letter Agreement (Filed With SEC on November 7, 2023)

Form of Restricted Stock Unit Agreement under (Filed With SEC on August 8, 2023)

Form of Restricted Stock Unit Agreement for Employees under the (Filed With SEC on August 8, 2023)

Form of Restricted Stock Unit Agreement for Non-Employee Directors under the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan (Filed With SEC on August 8, 2023)

Amendment 2 to the Collaboration and Commercial License Agreement, dated August 12, 2016, by and between Mersana Therapeutics, Inc. and Merck KGaA (Filed With SEC on May 9, 2023)

Amendment 3 to the Collaboration and Commercial License Agreement, dated February 28, 2017, by and between Mersana Therapeutics, Inc. and Merck KGaA (Filed With SEC on May 9, 2023)

License, Development and Commercialization Agreement, dated July 9, 2015, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A (Filed With SEC on May 9, 2023)

Agreement Regarding LICR Technology, dated July 9, 2015, by and between Ludwig Institute for Cancer Research, Recepta Biopharma S.A. and Mersana Therapeutics, Inc (Filed With SEC on May 9, 2023)

Amendment 1 to the Collaboration and Commercial License Agreement, dated June 1, 2016, by and between Mersana Therapeutics, Inc. and Merck KGaA (Filed With SEC on May 9, 2023)

Collaboration and Commercial License Agreement, dated June 23, 2014, by and between Mersana Therapeutics, Inc. and Merck KGaA (Filed With SEC on May 9, 2023)

Fourth Amendment to Loan and Security Agreement, dated March 23, 2023, between Oxford Finance LLC, the Lenders named therein including Silicon Valley Bridge Bank, N.A., and... (Filed With SEC on May 9, 2023)

Non-Employee Director Compensation Policy, effective as of December 1, 2022 (Filed With SEC on February 28, 2023)

2017 Employee Stock Purchase Plan (Filed With SEC on February 28, 2023)

Third Amendment to Loan and Security Agreement, dated December 27, 2022, between Oxford Finance LLC, the Lenders named therein including Silicon Valley Bank, and Mersana... (Filed With SEC on February 28, 2023)

Second Amendment to Loan and Security Agreement, dated October 17, 2022, between Oxford Finance LLC, the Lenders named therein including Silicon Valley Bank, and Mersana... (Filed With SEC on February 28, 2023)

Collaboration and Commercial License Agreement, dated December 22, 2022, between Mersana Therapeutics, Inc. and Ares Trading S.A (Filed With SEC on February 28, 2023)

Description of Securities (Filed With SEC on February 28, 2023)

Sales Agreement dated November 7, 2022 by and between the Company and Cowen and Company, LLC (Filed With SEC on November 7, 2022)

Research Collaboration and License Agreement, dated February 2, 2022, between the Company and Janssen Biotech, Inc (Filed With SEC on May 9, 2022)

Amendment No. 1 to the Amended and Restated Commercial License and Option Agreement, dated February 2, 2022, between the Company and Synaffix B.V (Filed With SEC on May 9, 2022)

First Amendment to Loan and Security Agreement, dated February 17, 2022, between Oxford Finance LLC, the Lenders named therein including Silicon Valley Bank, and the Company (Filed With SEC on May 9, 2022)

Offer Letter, dated March 5, 2021, between the Company and Alejandra Carvajal (Filed With SEC on May 9, 2022)

Offer Letter, dated June 15, 2021, between the Company and Tushar Misra (Filed With SEC on May 9, 2022)

Loan and Security Agreement, dated October 29, 2021, by and between Oxford Finance LLC, Silicon Valley Bank and Mersana Therapeutics, Inc (Filed With SEC on February 28, 2022)

Sales Agreement dated February 28, 2022 by and between the Company and Cowen and Company, LLC (Filed With SEC on February 28, 2022)

Form of Non-statutory Stock Option under the 2022 Inducement Stock Incentive Plan (Filed With SEC on February 28, 2022)

Form of Inducement Restricted Stock (Filed With SEC on February 28, 2022)

2022 Inducement Stock Incentive Plan (Filed With SEC on February 28, 2022)

Amended and Restated Commercial License and Option Agreement, dated November 23, 2021, by and between Synaffix B.V. and Mersana Therapeutics, Inc (Filed With SEC on February 28, 2022)

Second Amendment to the License, Development and Commercialization Agreement, dated September 28, 2021, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A.... (Filed With SEC on November 9, 2021)

Form of Restricted Stock Unit under the 2017 Stock Incentive Plan (Filed With SEC on August 6, 2021)

Amended and Restated Offer Letter, by and between Mersana Therapeutics, Inc. and Michael Kaufman, dated March 8, 2017 (Filed With SEC on May 10, 2021)

Offer Letter, by and between Mersana Therapeutics, Inc. and Arvin Yang, dated November 5, 2020 (Filed With SEC on May 10, 2021)

Eighth Lease Modification Agreement to the Lease Between Rivertech Associates II LLC and Mersana Therapeutics, Inc., effective as of April 5, 2021, by and between Mersana... (Filed With SEC on May 10, 2021)

Second Amendment to Loan and Security Agreement, dated August 28, 2020, by and between Mersana Therapeutics, Inc, and Silicon Valley Bank (Filed With SEC on September 3, 2020)

Commercial License and Option Agreement (Filed With SEC on August 7, 2020)

Underwriting Agreement, dated May 28, 2020, among Mersana Therapeutics, Inc. and Cowen and Company, LLC and SVB Leerink LLC, as representatives of the several underwriters listed... (Filed With SEC on June 1, 2020)

Offer Letter, by and between Mersana Therapeutics, Inc. and Dirk Huebner, dated November 5, 2018 (Filed With SEC on May 8, 2020)

Seventh Lease Extension and Modification Agreement to the Lease Between Rivertech Associates II LLC and Mersana Therapeutics, Inc. dated March 10 2020, by and between Mersana... (Filed With SEC on May 8, 2020)

Offer Letter, by and between Mersana Therapeutics, Inc. and Brian DeSchuytner, dated June 10, 2019 (Filed With SEC on May 8, 2020)

Description of Registrants Common Stock (Filed With SEC on February 28, 2020)

Exchange Agreement between Mersana Therapeutics, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P. and Biotechnology Value Trading Fund OS, L.P., dated... (Filed With SEC on November 27, 2019)

Form of Exchange Warrant (Filed With SEC on November 27, 2019)

First Amendment to the License, Development and Commercialization Agreement dated August 19, 2019, by and between Mersana Therapeutics, Inc. and Recepta Biopharma, S.A (Filed With SEC on November 6, 2019)

First Amendment to Loan and Security Agreement, dated June 21, 2019, by and between Mersana Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on August 8, 2019)

Loan and Security Agreement dated May 8, 2019, by and between Mersana Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on August 8, 2019)

Offer Letter, by and between Mersana Therapeutics, Inc. and David Spellman, dated December 18, 2017 (Filed With SEC on May 9, 2019)

Loan and Security Agreement dated May 8, 2019, by and between Mersana Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on May 9, 2019)

Underwriting Agreement, dated February 28, 2019, by and among Mersana Therapeutics, Inc. and SVB Leerink LLC, as the representative of the several underwriters listed on Schedule... (Filed With SEC on March 4, 2019)

Amendment 4 to Collaboration and Commercial License Agreement dated May 15, 2018, by and between Mersana Therapeutics, Inc. and Merck KGaA (Filed With SEC on August 14, 2018)

Sixth Lease Extension and Modification Agreement, dated January 17, 2018, by and between Mersana Therapeutics, Inc. and Rivertech Associates II LLC (Filed With SEC on May 15, 2018)

Third Amendment to Amended and Restated Research Collaboration and Commercial License Agreement, dated October 30, 2017, by and between Mersana Therapeutics, Inc. and Millennium... (Filed With SEC on November 13, 2017)

SECOND AMENDMENT TO AMENDED AND RESTATED RESEARCH COLLABORATION AND COMMERCIAL LICENSE AGREEMENT (Filed With SEC on August 11, 2017)

MERSANA THERAPEUTICS, INC. [] Shares of Common Stock, par value $0.0001 per share Underwriting Agreement (Filed With SEC on June 16, 2017)

MERSANA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on June 16, 2017)

MERSANA THERAPEUTICS, INC. 2017 STOCK INCENTIVE PLAN (Filed With SEC on June 16, 2017)

MERSANA THERAPEUTICS, INC. 2017 STOCK INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on June 16, 2017)

MERSANA THERAPEUTICS, INC. 2017 STOCK INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on June 16, 2017)

MERSANA THERAPEUTICS, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on June 16, 2017)

MERSANA THERAPEUTICS, INC. 2017 CASH BONUS PLAN (Filed With SEC on June 16, 2017)

WARRANT TO PURCHASE COMMON STOCK OF MERSANA THERAPEUTICS, INC. (A DELAWARE CORPORATION) SEPTEMBER 27, 2013 (Filed With SEC on June 1, 2017)

CONFIDENTIAL LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between MERSANA THERAPEUTICS, INC. and RECEPTA BIOPHARMA S.A. (Filed With SEC on June 1, 2017)

MERSANA THERAPEUTICS, INC. THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on June 1, 2017)

INDENTURE OF LEASE by and between RIVERTECH ASSOCIATES II, LLC (LESSOR) and MERSANA THERAPEUTICS, INC. (LESSEE) (Filed With SEC on June 1, 2017)

RIVERSIDE TECHNOLOGY CENTER FIFTH LEASE EXTENSION AND MODIFICATION AGREEMENT TO THE LEASE BETWEEN RIVERTECH ASSOCIATES II LLC AND MERSANA THERAPEUTICS, INC. (Filed With SEC on June 1, 2017)

CONFIDENTIAL COLLABORATION AND COMMERCIAL LICENSE AGREEMENT between MERSANA THERAPEUTICS, INC. and MERCK KGaA (Filed With SEC on June 1, 2017)

CONFIDENTIAL AMENDMENT 1 TO COLLABORATION AND COMMERCIAL LICENSE AGREEMENT (Filed With SEC on June 1, 2017)

CONFIDENTIAL AMENDMENT 2 TO COLLABORATION AND COMMERCIAL LICENSE AGREEMENT (Filed With SEC on June 1, 2017)

CONFIDENTIAL AMENDMENT 3 TO COLLABORATION AND COMMERCIAL LICENSE AGREEMENT (Filed With SEC on June 1, 2017)

CONFIDENTIAL AMENDMENT NUMBER ONE to the COLLABORATION AGREEMENT (Filed With SEC on June 1, 2017)

CONFIDENTIAL COLLABORATION AGREEMENT BY AND BETWEEN ADIMAB, LLC AND MERSANA THERAPEUTICS, INC. JULY 25, 2012 [***] Portions of this exhibit have been redacted pursuant to a... (Filed With SEC on June 1, 2017)

CONFIDENTIAL (Filed With SEC on June 1, 2017)

Category

Industry

Companies

Contracts

Mersana Therapeutics, Inc. Contracts & Agreements